All In Biotech

Drug Trial Radar · NCT04650854

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Feb 3, 2021

Primary completion

Jan 25, 2024

Study completion Jan 25, 2024

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Dec 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • RozanolixizumabDrug

    Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Baseline (Day 1) to End of Study (up to 34 months)
  2. Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP)Time frame: From Baseline (Day 1) to End of Study (up to 34 months)

Locations

69 sites in 14 countries. Site status is shown where the registry gives one.

  • Mg0007 50092

    Orange, California

  • Mg0007 50099

    San Francisco, California

  • Mg0007 50122

    Miami, Florida

  • Mg0007 50120

    Miami, Florida

  • Mg0007 50073

    Tampa, Florida

  • Mg0007 50075

    Augusta, Georgia

  • Mg0007 50323

    Honolulu, Hawaii

  • Mg0007 50114

    Indianapolis, Indiana

  • Mg0007 50121

    Lexington, Kentucky

  • Mg0007 50077

    New York, New York

  • Mg0007 50090

    Winston-Salem, North Carolina

  • Mg0007 50096

    Philadelphia, Pennsylvania

  • Mg0007 50113

    Houston, Texas

  • Mg0007 50071

    Edmonton, Canada

  • Mg0007 50066

    Montreal, Canada

  • Mg0007 50124

    Montreal, Canada

  • Mg0007 50070

    Québec, Canada

  • Mg0007 50069

    Toronto, Canada

  • Mg0007 40125

    Ostrava - Poruba, Czechia

  • Mg0007 40124

    Prague, Czechia

  • Mg0007 40128

    Aalborg, Denmark

  • Mg0007 40127

    Aarhus, Denmark

  • Mg0007 40126

    Copenhagen, Denmark

  • Mg0007 40129

    Bordeaux, France

  • Mg0007 40360

    Limoges, France

  • Mg0007 40132

    Nice, France

  • Mg0007 40133

    Paris, France

  • Mg0007 40131

    Strasbourg, France

  • Mg0007 20160

    Tbilisi, Georgia

  • Mg0007 20161

    Tbilisi, Georgia

  • Mg0007 20163

    Tbilisi, Georgia

  • Mg0007 20164

    Tbilisi, Georgia

  • Mg0007 20165

    Tbilisi, Georgia

  • Mg0007 40134

    Essen, Germany

  • Mg0007 40140

    Göttingen, Germany

  • Mg0007 40139

    Jena, Germany

  • Mg0007 40078

    Leipzig, Germany

  • Mg0007 40177

    Münster, Germany

  • Mg0007 40283

    Bologna, Italy

  • Mg0007 40144

    Milan, Italy

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.